Business Wire

FDA Grants 510(k) Clearance for Abiomed’s Innovative Cardiopulmonary Support Technology

Share

The United States Food and Drug Administration (FDA) has granted Abiomed (NASDAQ: ABMD) a 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System™.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005299/en/

The Abiomed Breethe OXY-1 System has received 510(k) clearance from the United States FDA (Photo: Buisness Wire)

The Abiomed Breethe OXY-1 System has received 510(k) clearance from the United States FDA (Photo: Buisness Wire)

The ECMO system provides cardiopulmonary bypass support for patients whose lungs can no longer provide sufficient end organ oxygenation. The 510(k) clearance is to pump, oxygenate, and remove carbon dioxide from blood during cardiopulmonary bypass for up to six hours. The system can help provide oxygenation to patients suffering from cardiogenic shock or respiratory failure such as ARDS, H1N1, SARS, or COVID-19. When used with the Impella heart pump it can unload the heart and oxygenate the body, a combination therapy known as ECpella.

Abiomed’s Breethe technology is a novel, easy-to-use cardiopulmonary bypass system that is designed for mobility. The components of the system are designed to reduce the overall equipment footprint, support patient ambulation, and provide an intuitive interface for health care providers to setup and manage. The integrated pump lung unit is engineered with volute spiral technology for uniform blood flow with minimal stagnation and advanced gas exchange technology that allows for full therapy with reduced oxygen requirements.

“As a leader in technology and innovation, the Breethe system is a natural addition to Abiomed’s existing product portfolio,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer. “This ECMO technology will allow us to support new patient populations, such as COVID-19 patients and others who need lung support, and provide combination ECpella therapy to Impella patients who need oxygenation. Furthermore, we will advance the field of native lung recovery and improve patient outcomes by collecting critical research data and developing and teaching best practices.”

“Abiomed has a long-established track record of bringing to market improved options to support physicians with innovative technology like Breethe, which is designed to provide advanced respiratory and cardiac support,” said Bartley Griffith, MD, the Hales Distinguished Professor of Surgery at University of Maryland, School of Medicine. “Abiomed is committed to advancing heart and lung therapies to help improve patient care and ultimately outcomes.”

“The clinical community has long been in need of innovation compared to traditional extracorporeal circulation therapy,” said Dr. Zachary Kon, cardiothoracic surgeon at New York University. “The Breethe system is a breakthrough technology because it supports transition from bed to ambulation via system portability. This system has the potential to revolutionize the way we think about extracorporeal life support therapy and can improve patient care.”

To help health care providers achieve the best possible outcomes, the Breethe system will be supported 24 hours a day, 7 days a week by Abiomed’s experienced field-based, in-hospital clinical team and on-call team from the Clinical Support Center.

This ECMO technology adds to Abiomed’s innovative portfolio focused on native heart and lung recovery. For many patients in cardiogenic shock, Abiomed now provides the treatment options of both the catheter-based Impella heart pump, which unloads the left ventricle, perfuses end organs and allows the heart to rest and recover, and Breethe, which provides oxygenation. Impella and Breethe can work together as ECpella to unload the heart and oxygenate the body.

Multiple studies support the association of ECpella therapy to improve outcomes for patients who are suffering from cardiogenic shock and require oxygenation. A study published this month in Circulation examined data from 686 consecutive patients at 16 tertiary-care centers from four countries and found ECpella was associated with increased 30-day survival (43% vs 37%; p=0.03). The European Journal of Heart Failure, ASAIO, and the Journal of the American College of Cardiology have published studies that conclude use of ECpella was associated with increased survival rates, as compared to patients who were treated with ECMO only. This benefit is not seen in patients treated with ECMO combined with the intra-aortic balloon pump (IABP). (see figure 1) Additionally, the study in the European Journal of Heart Failure found higher rates of heart recovery with ECpella use than with ECMO only (62% vs 36%; p=0.048).

In August, the FDA issued an emergency use authorization (EUA) for all left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing ECMO treatment and develop pulmonary edema or myocarditis.

Abiomed plans to have a controlled launch of the Breethe system at hospitals in the United States, with full U.S. commercial availability expected in calendar year 2021.

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.

ABOUT ABIOMED BREETHE OXY-1 SYSTEM

The Abiomed Breethe OXY-1 System™ is cleared by the U.S. Food and Drug Administration (FDA) to provide extracorporeal circulation. The OXY-1 System pumps, oxygenates and removes carbon dioxide from blood during cardiopulmonary bypass up to six (6) hours in duration.

Under guidance issued by FDA, on April 6, 2020, the Abiomed Breethe OXY-1 System is now permitted to be used temporarily in the U.S. for ECMO therapy greater than six hours. Therefore, it now has a limited indication modification for use longer than six hours in an extracorporeal membrane oxygenation (ECMO) circuit to treat patients who are experiencing acute temporary respiratory or acute cardiopulmonary failure. This limited indication modification for ECMO therapy greater than six hours has not been cleared or approved by FDA and is in effect only for the duration of the public health emergency related to COVID-19 as declared by the U.S. Department of Health and Human Services (HHS).

ABOUT IMPELLA HEART PUMPS

The Impella 2.5®, Impella CP®, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.

Impella Left Ventricular (LV) Support Systems are also authorized for emergency use by HCPs in the hospital setting for providing temporary (≤ 4 days for Impella 2.5, Impella CP, and Impella CP with SmartAssist; and ≤ 14 days for Impella 5.0 and Impella 5.5 with SmartAssist) LV unloading and support to treat critical care patients with confirmed COVID-19 infection who are undergoing ECMO treatment and who develop pulmonary edema while on V-A ECMO support or late cardiac decompensation from myocarditis while on V-V ECMO support. The authorized Impella LV Support Systems have neither been cleared or approved for the authorized indication for use. The Impella RP and Impella LV Support Systems have been authorized for the above emergency use by FDA under an EUA and have been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contact information

Tom Langford
Director of Communication
(978) 882-8408
TLangford@abiomed.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MEDIROM Healthcare Technologies Inc. Announces Filing of Registration Statement for Proposed Initial Public Offering on NASDAQ25.11.2020 16:00:00 CETPress release

MEDIROM Healthcare Technologies Inc. (“MEDIROM”), the healthcare company which runs branded relaxation salons in Japan, today announced it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its American Depositary Receipts which represent the common shares of the Company. The number of ADRs to be offered and the price range for the proposed offering have not yet been determined. MEDIROM has applied to list its ADR on Nasdaq Capital Market. Maxim Group LLC is acting as lead manager and representative of the underwriters for the offering. The proposed offering will be made only by means of a prospectus. Once available, a copy of the preliminary prospectus related to the offering may be obtained at the SEC's website at http://www.sec.gov or from the offices of Maxim Group LLC, Attention: Prospectus Department, 405 Lexington Ave Second Floor, New York, NY 10174, telephone: 1-212-

Xinhuanet: Chengdu’s Talent Appeal Spurs the City’s Embrace of the World25.11.2020 15:39:00 CETPress release

“Chengdu is increasingly attracting skilled talent and entrepreneurs to integrate, put down roots, and start businesses in the city. The city continues to become more appealing, which in turn further promotes its international development,” said Xu Wen, head of Southwestern business at PwC’s Chengdu branch. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005704/en/ Xu Wen, head of Southwestern business at PwC’s Chengdu branch, takes a media interview (Photo: Business Wire) In the “City of Opportunity 2020” report released by PwC this year, Chengdu ranked 5th in China, only surpassed by Beijing, Shanghai, Guangzhou, and Shenzhen. Xu sees Chengdu’s great advantage as a “new first-tier” city reflected in the city’s appeal to skilled talent. “With China’s economy undergoing transformation and upgrading, innovation capabilities are becoming more and more important. In this context, cultivating developmental advantages is a c

ViacomCBS to Sell Simon & Schuster to Penguin Random House for $2.175 Billion25.11.2020 15:00:00 CETPress release

ViacomCBS Inc. (NASDAQ: VIAC, VIACA) today announced it has entered into a definitive agreement to sell the publishing business Simon & Schuster (“Simon & Schuster”) to Penguin Random House LLC (“Penguin Random House”), a wholly owned subsidiary of Bertelsmann SE & Co. KGaA, for $2.175 billion in cash. This divesture follows a strategic review of non-core assets ViacomCBS undertook early in 2020. Proceeds from the transaction will be used to invest in ViacomCBS’s strategic growth priorities, including in streaming, as well as to fund the dividend and pay down debt. This transaction is the outcome of a highly competitive auction that attracted interest from buyers around the world, reflecting Simon & Schuster’s position as one of the world’s best known publishing brands. Simon & Schuster has more than 30 publishing units across adult, children, audio and international. Its portfolio of best-selling authors includes Stephen King, Doris Kearns Goodwin and Jason Reynolds, and it owns a ric

Enhancing the HD-PLC™ Security Functions25.11.2020 15:00:00 CETPress release

HD-PLC Alliance *1 has started standardization work that will allow the use of enhanced network security functions, with the aim of using High-Definition Power Line Communication technology in the fields of smart grids and distributed power management. HD-PLC™*2 (hereinafter referred to as HD-PLC) technology has already been standardized as IEEE 1901 (Broadband over Power Line Networks for MAC and PHY) by the IEEE Standards Association*3 . This technology is particularly attracting attention in Europe as a communication infrastructure that can be used for distributed power management of energy. Therefore, the current security functions will be enhanced and expanded, including making the technology compatible with strong authentication functions required for use in large-scale networks. Current HD-PLC technology offers extremely high security at the device level, including continuous encrypted communication and authentication between compatible devices. However, for PLC equipment to be

Northern Data AG Commissions First Data Center in the Netherlands25.11.2020 14:11:00 CETPress release

Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87), a leading provider of High-Performance Computing (HPC) solutions, is commissioning its latest HPC data center near Maastricht. This new facility will entail one of the largest GPU clusters worldwide and will be the Company's first data center location in the European Union. The Company will begin installing the first hardware for its GPU-based Distributed Computing Cluster from the beginning of December. The GPU cluster is one of Northern Data AG's most significant expansion steps and is expected to be scaled up by the end of Q1/2021 to achieve computing power of 404 Petaflops (FP64). With this level of power, it will be one of the largest GPU clusters of its kind worldwide. The world's most powerful supercomputer, Japan's Fugaku, has a computing capacity of 415 Petaflops. As CEO Aroosh Thillainathan commented: "With the smooth and rapid expansion of our GPU cluster, now including our first European location, we are moving to meet the

LexFinance Announced a Favorable Partial Award in a US$ 28 Billion Arbitration Against Brazil and for the Benefit of Petrobras25.11.2020 14:00:00 CETPress release

LexFinance announced a favorable partial award in a US$ 28 billion arbitration against Brazil and for the benefit of Petrobras. The claim has been filed by a minority shareholder of Petrobras against the Brazilian Government for the economic losses suffered by Petrobras due to corruption practices disclosed in the Car Wash investigation and caused by the abuse of power of the Brazilian Government as controlling shareholder of Petrobras. The partial award recognized the arbitrability of the dispute, that the Brazilian Government is subject to the arbitration clause and the standing of the claimant funded by LexFinance to act on behalf and for the benefit of Petrobras. If the damages are confirmed in the last phase of the arbitration expected to conclude during 2021, the Brazilian Government will have to compensate Petrobras for losses currently estimated at US$ 28 billion. In addition, according to article 246 of the Brazilian Corporate Law, it will have to pay to the claimant funded by